Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 7 | 2024 | 3048 | 0.660 |
Why?
|
| HIV Infections | 25 | 2024 | 17347 | 0.650 |
Why?
|
| Anti-HIV Agents | 13 | 2024 | 4526 | 0.500 |
Why?
|
| Sarcoma, Kaposi | 3 | 2024 | 374 | 0.500 |
Why?
|
| Disease Outbreaks | 3 | 2021 | 1747 | 0.440 |
Why?
|
| RNA, Viral | 10 | 2023 | 2839 | 0.360 |
Why?
|
| Viral Load | 6 | 2024 | 3328 | 0.320 |
Why?
|
| Antibodies, Viral | 6 | 2024 | 3149 | 0.310 |
Why?
|
| Nucleosomes | 1 | 2012 | 486 | 0.300 |
Why?
|
| Influenza, Human | 2 | 2016 | 1521 | 0.280 |
Why?
|
| Lamivudine | 2 | 2018 | 366 | 0.280 |
Why?
|
| Anti-Retroviral Agents | 3 | 2021 | 1784 | 0.260 |
Why?
|
| Population Surveillance | 1 | 2016 | 2598 | 0.260 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2018 | 287 | 0.250 |
Why?
|
| Cytomegalovirus Infections | 2 | 2023 | 828 | 0.250 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2024 | 80 | 0.230 |
Why?
|
| Control Groups | 1 | 2023 | 104 | 0.220 |
Why?
|
| Virus Shedding | 2 | 2023 | 109 | 0.200 |
Why?
|
| Herpesvirus 8, Human | 1 | 2024 | 255 | 0.200 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2016 | 447 | 0.200 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2024 | 662 | 0.180 |
Why?
|
| Biological Assay | 1 | 2023 | 623 | 0.180 |
Why?
|
| Atrial Fibrillation | 6 | 2014 | 5114 | 0.180 |
Why?
|
| Alkynes | 1 | 2021 | 320 | 0.180 |
Why?
|
| South Africa | 2 | 2016 | 1843 | 0.170 |
Why?
|
| Chromatin | 1 | 2012 | 2946 | 0.170 |
Why?
|
| Cyclopropanes | 1 | 2021 | 432 | 0.170 |
Why?
|
| Benzoxazines | 1 | 2021 | 316 | 0.170 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2019 | 75 | 0.170 |
Why?
|
| Cytomegalovirus | 2 | 2023 | 750 | 0.170 |
Why?
|
| Nitriles | 2 | 2022 | 971 | 0.160 |
Why?
|
| Pyrimidines | 2 | 2022 | 3027 | 0.160 |
Why?
|
| Adult | 33 | 2024 | 221119 | 0.160 |
Why?
|
| HIV | 6 | 2023 | 1581 | 0.160 |
Why?
|
| Bleomycin | 1 | 2020 | 495 | 0.160 |
Why?
|
| Galectins | 1 | 2021 | 296 | 0.160 |
Why?
|
| Humans | 60 | 2024 | 761208 | 0.160 |
Why?
|
| Genitalia | 1 | 2018 | 113 | 0.150 |
Why?
|
| Body Composition | 2 | 2019 | 2427 | 0.150 |
Why?
|
| DNA | 1 | 2012 | 7189 | 0.150 |
Why?
|
| Arginine | 1 | 2021 | 920 | 0.150 |
Why?
|
| Osteoprotegerin | 1 | 2018 | 177 | 0.150 |
Why?
|
| Vincristine | 1 | 2020 | 1036 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2012 | 5081 | 0.140 |
Why?
|
| DNA, Viral | 2 | 2023 | 2195 | 0.140 |
Why?
|
| RANK Ligand | 1 | 2018 | 318 | 0.130 |
Why?
|
| Inflammation | 4 | 2023 | 10759 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 8 | 2024 | 9187 | 0.130 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2022 | 2196 | 0.130 |
Why?
|
| Middle Aged | 27 | 2024 | 220853 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 677 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2024 | 4015 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 620 | 0.130 |
Why?
|
| Hong Kong | 1 | 2015 | 164 | 0.120 |
Why?
|
| Bone Density | 2 | 2020 | 3546 | 0.120 |
Why?
|
| Death | 1 | 2019 | 677 | 0.120 |
Why?
|
| Herpesvirus 4, Human | 1 | 2020 | 1076 | 0.120 |
Why?
|
| Male | 34 | 2024 | 360693 | 0.120 |
Why?
|
| Singapore | 1 | 2015 | 292 | 0.120 |
Why?
|
| Pyrazoles | 2 | 2022 | 2010 | 0.110 |
Why?
|
| Abdominal Fat | 1 | 2016 | 221 | 0.110 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2015 | 137 | 0.110 |
Why?
|
| Antibodies, Neutralizing | 4 | 2024 | 1935 | 0.110 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 614 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2021 | 1895 | 0.110 |
Why?
|
| Female | 34 | 2024 | 392544 | 0.110 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 643 | 0.110 |
Why?
|
| Waist Circumference | 1 | 2017 | 933 | 0.110 |
Why?
|
| Contact Tracing | 1 | 2015 | 272 | 0.100 |
Why?
|
| HIV-1 | 3 | 2018 | 6851 | 0.100 |
Why?
|
| Japan | 1 | 2016 | 1378 | 0.100 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 675 | 0.100 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 612 | 0.100 |
Why?
|
| Outpatients | 3 | 2024 | 1598 | 0.100 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 561 | 0.090 |
Why?
|
| C-Reactive Protein | 3 | 2021 | 3821 | 0.090 |
Why?
|
| Genome, Fungal | 1 | 2012 | 202 | 0.090 |
Why?
|
| Hospitalization | 3 | 2024 | 10707 | 0.090 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2014 | 702 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2015 | 2928 | 0.080 |
Why?
|
| Aged | 13 | 2024 | 169288 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2014 | 24021 | 0.080 |
Why?
|
| Markov Chains | 1 | 2012 | 965 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 1803 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2022 | 3952 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2019 | 3313 | 0.070 |
Why?
|
| Subcutaneous Fat | 2 | 2021 | 393 | 0.070 |
Why?
|
| Adiposity | 1 | 2017 | 1879 | 0.070 |
Why?
|
| Bayes Theorem | 1 | 2015 | 2329 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 4947 | 0.070 |
Why?
|
| Age Factors | 4 | 2016 | 18384 | 0.070 |
Why?
|
| Drug Resistance, Viral | 2 | 2024 | 862 | 0.070 |
Why?
|
| HIV Protease Inhibitors | 2 | 2021 | 432 | 0.070 |
Why?
|
| Oxazines | 2 | 2018 | 349 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2024 | 6304 | 0.070 |
Why?
|
| Kinetics | 2 | 2023 | 6312 | 0.060 |
Why?
|
| Myocardial Infarction | 4 | 2021 | 11476 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 1725 | 0.060 |
Why?
|
| Protease Inhibitors | 2 | 2020 | 752 | 0.060 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2024 | 46 | 0.060 |
Why?
|
| Ritonavir | 2 | 2016 | 329 | 0.060 |
Why?
|
| Menopause | 1 | 2012 | 1646 | 0.060 |
Why?
|
| Hypoalbuminemia | 1 | 2024 | 86 | 0.060 |
Why?
|
| ROC Curve | 1 | 2012 | 3584 | 0.060 |
Why?
|
| Pandemics | 1 | 2023 | 8663 | 0.050 |
Why?
|
| WT1 Proteins | 1 | 2024 | 184 | 0.050 |
Why?
|
| Pyridones | 2 | 2018 | 809 | 0.050 |
Why?
|
| Half-Life | 1 | 2023 | 649 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2014 | 5103 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2015 | 6224 | 0.050 |
Why?
|
| Basic Reproduction Number | 1 | 2021 | 36 | 0.050 |
Why?
|
| Prospective Studies | 7 | 2021 | 54435 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2021 | 362 | 0.050 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2012 | 2667 | 0.050 |
Why?
|
| Heart Failure | 3 | 2013 | 11701 | 0.040 |
Why?
|
| Young Adult | 5 | 2019 | 59221 | 0.040 |
Why?
|
| Janus Kinases | 1 | 2021 | 248 | 0.040 |
Why?
|
| Adipokines | 1 | 2022 | 307 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2024 | 1695 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2023 | 12341 | 0.040 |
Why?
|
| Subcutaneous Fat, Abdominal | 1 | 2019 | 91 | 0.040 |
Why?
|
| Weight Gain | 2 | 2022 | 2349 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20588 | 0.040 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2019 | 138 | 0.040 |
Why?
|
| Etoposide | 1 | 2020 | 635 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2024 | 2048 | 0.040 |
Why?
|
| Body Fat Distribution | 1 | 2019 | 245 | 0.040 |
Why?
|
| Incidence | 5 | 2014 | 21365 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 58952 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 858 | 0.040 |
Why?
|
| Piperazines | 2 | 2018 | 2522 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 714 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2024 | 64681 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2021 | 1417 | 0.030 |
Why?
|
| Stroke | 2 | 2021 | 9721 | 0.030 |
Why?
|
| Immune System | 1 | 2021 | 792 | 0.030 |
Why?
|
| Morbidity | 1 | 2021 | 1751 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2024 | 2444 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 1186 | 0.030 |
Why?
|
| Aging | 1 | 2014 | 8702 | 0.030 |
Why?
|
| Algorithms | 2 | 2013 | 14025 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 36169 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2020 | 1738 | 0.030 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 12474 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 42224 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 20119 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2014 | 862 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 2021 | 1390 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 1838 | 0.030 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2015 | 165 | 0.030 |
Why?
|
| Heart Murmurs | 1 | 2013 | 92 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2021 | 22174 | 0.030 |
Why?
|
| RNA | 1 | 2023 | 2709 | 0.030 |
Why?
|
| Iceland | 1 | 2013 | 184 | 0.030 |
Why?
|
| Risk Factors | 5 | 2024 | 74239 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2020 | 1730 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2023 | 2770 | 0.030 |
Why?
|
| Vaccination | 1 | 2024 | 3369 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 621 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2021 | 3210 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1867 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 4537 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2024 | 3551 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 14610 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 3873 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 15308 | 0.020 |
Why?
|
| Body Weight | 1 | 2021 | 4618 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 2227 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4851 | 0.020 |
Why?
|
| Recurrence | 1 | 2022 | 8457 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2017 | 6223 | 0.020 |
Why?
|
| Child | 1 | 2016 | 80152 | 0.020 |
Why?
|
| Netherlands | 1 | 2013 | 2222 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 88298 | 0.020 |
Why?
|
| Age Distribution | 1 | 2014 | 2871 | 0.020 |
Why?
|
| Time Factors | 2 | 2023 | 39957 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2013 | 854 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6781 | 0.020 |
Why?
|
| Developing Countries | 1 | 2020 | 2863 | 0.020 |
Why?
|
| Europe | 1 | 2014 | 3423 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2017 | 12952 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2023 | 80674 | 0.020 |
Why?
|
| Software | 1 | 2021 | 4431 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10088 | 0.020 |
Why?
|
| Linear Models | 1 | 2016 | 5869 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 26071 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2016 | 4009 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2013 | 41496 | 0.020 |
Why?
|
| Self Report | 1 | 2017 | 3727 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2018 | 8642 | 0.010 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 5842 | 0.010 |
Why?
|
| Prevalence | 1 | 2021 | 15721 | 0.010 |
Why?
|
| Prognosis | 2 | 2014 | 29687 | 0.010 |
Why?
|
| Overweight | 1 | 2013 | 2418 | 0.010 |
Why?
|
| United States | 3 | 2014 | 72339 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 12728 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12052 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11733 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 30002 | 0.010 |
Why?
|
| Smoking | 1 | 2013 | 9055 | 0.010 |
Why?
|
| Hypertension | 1 | 2013 | 8536 | 0.010 |
Why?
|
| Neoplasms | 1 | 2021 | 22140 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 39126 | 0.010 |
Why?
|
Concepts
(203)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_